Sigma Advanced System has completed the divestment of its entire 36.52% equity stake in Extrovis AG, a Switzerland-based pharmaceutical company. The transaction has generated $15 million (approximately Rs 137.61 crore), providing the company with additional financial flexibility as it accelerates the expansion of its aerospace and defence business.

The divestment forms part of Sigma's ongoing portfolio rationalisation strategy, and the company has transformed into a pureplay aerospace and defence platform. By exiting a non-core pharmaceutical investment, Sigma is freeing up capital that can now be deployed toward strengthening manufacturing capabilities, pursuing strategic acquisitions, and expanding its presence across global defence and aerospace supply chains.